Uppsala, 2017-09-11 22:05 CEST (GLOBE NEWSWIRE) —
With the occasion of the publication of the EMAs agenda for the CHMP meeting-11 – september 14, hereby announces Oasmia Pharmaceutical AB (NASDAQ: OASM) that the requested clock-stop of the process regarding the application for marketing authorisation for the Apealea® in Europe to be given additional time to respond on previous outstanding issues from day 180.
Link to the agenda:
Notes to editors:
If Oasmia Pharmaceutical AB
(NASDAQ Stockholm: OASM) Oasmia Pharmaceutical AB develops, manufactures, markets and sells a new generation of drugs within human and veterinary oncology. The product development aims to produce novel formulations containing nanoparticles of well-established cytostatics which, in comparison with the existing options have enhancement characteristics, improved side-effect profile and broader application areas. Product development is based on own research within nanotechnology and proprietary patents. The company’s share is listed on the NASDAQ in Stockholm, Frankfurt Stock Exchange and the NASDAQ Capital Markets.